Century Therapeutics, Inc.

Name: Century Therapeutics, Inc. standardized financial statements, quarterly
Creator: Listed

IPSCNasdaqCIK 1850119HealthcareFiscal year ends Dec 31

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$0, Q4 FY2025

Operating income−$36.5m, Q2 FY2026

Net income−$34.5m, Q2 FY2026

Century Therapeutics, Inc., income statement, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Revenue	$m	0.1	0.3	0.9	0.8	0.8	4.2	109	0.0	0.0	0.0	not reported	not reported
Research and development	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	0.0	not reported	not reported	not reported
Operating income	$m	(35.6)	(43.8)	(31.3)	(34.8)	(34.8)	(37.3)	74.2	(34.7)	(36.1)	(20.7)	(23.7)	(36.5)
Interest expense	$m	0.0	1.1	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Income tax	$m	0.6	(0.9)	0.0	0.0	(0.0)	1.8	not reported	not reported	not reported	not reported	not reported	not reported
Net income	$m	(32.7)	(39.4)	(28.1)	(31.2)	(31.2)	(36.1)	76.6	(32.5)	(34.4)	(19.2)	(21.6)	(34.6)
Diluted EPS	$ per share	(0.55)	not reported	(0.45)	(0.38)	(0.37)	not reported	0.89	(0.38)	(0.40)	not reported	(0.11)	(0.17)
Basic EPS	$ per share	(0.55)	not reported	(0.45)	(0.38)	(0.37)	not reported	0.89	(0.38)	(0.40)	not reported	(0.11)	(0.17)

Balance sheet

Cash and equivalents$49.6m, Q2 FY2026

Shareholders' equity$232.3m, Q2 FY2026

Century Therapeutics, Inc., balance sheet, quarterly
Line item	Unit	Q3 FY20232023-09-30	FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Cash and equivalents	$m	55.3	47.3	46.8	41.5	52.6	58.4	51.9	56.9	55.5	61.9	51.0	49.6
Current assets	$m	174	177	200	203	206	194	170	160	138	121	139	125
Total assets	$m	398	361	349	416	389	353	316	285	245	224	327	287
Current liabilities	$m	20.4	17.8	16.1	19.2	19.8	130	14.5	14.9	22.0	20.2	13.6	15.1
Total liabilities	$m	178	176	171	194	193	192	75.2	74.8	68.4	64.8	61.8	54.7
Long-term debt	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Shareholders' equity	$m	219	185	178	222	196	161	240	210	176	159	265	232

Cash flow

Operating cash flow−$19.8m, Q2 FY2026

Capital expenditure$694.0k, Q2 FY2026

Century Therapeutics, Inc., cash flow, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Operating cash flow	$m	(13.6)	(26.2)	(30.2)	(27.3)	(28.3)	(24.2)	(34.6)	(27.6)	(25.6)	(16.1)	(25.3)	(19.8)
Capital expenditure	$m	3.3	1.0	0.5	0.3	not reported	not reported	0.5	0.3	0.2	(0.1)	0.6	0.7

Diluted shares (weighted)205.78m, Q2 FY2026

Century Therapeutics, Inc., shares, quarterly
Line item	Unit	Q3 FY20222022-09-30	Q1 FY20232023-03-31	Q2 FY20232023-06-30	Q3 FY20232023-09-30	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Diluted shares (weighted)	m shares	58.0	58.6	59.3	59.4	62.3	82.1	84.7	86.1	86.2	86.5	193	206

Shares outstanding: 181.08m at Aug 3, 2026, from the cover of the 10-Q filed Aug 12, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:49 ET. Listed shows no prices and gives no investment advice.